However, the protein complex was mainly excreted after two hours in contrast to IGF-1/NP which accumulation in liver was over 17%ID/g at the same time point. It has been shown that intravenously administered mesoporous silicon microparticles loaded with siRNA encapsulated into nanoliposomes accumulate into the liver and spleen, but remain in the sinusoidal space, enabling sustained release of siRNA-loaded nanoliposomes [52]. Inhibitors,research,lifescience,medical In our other studies we have analyzed behavior of I-125 labeled thermally hydrocarbonized mesoporous

silicon nanoparticles in liver using combined data of autoradiography and electron microscopy [53]. Similar nanoparticles as used in this study were seen in hepatic veins and sinusoids but not internalized into macrophages or hepatocytes. In addition, Bimbo et al. reported that THCPSi nanoparticles are not phagocytes in extent by CaCo-2 or RAW 264.7 macrophages Inhibitors,research,lifescience,medical in vitro. Instead they showed a strong cellular association as majority of the nanoparticles remained attached to cell membranes [54]. We suggest that IGF-1/NP is intact in the liver and IGF-1 may be released during the 240min studied, whereas IGF-1/IGFBP-3 is cleared trough

hepatic system. This can be seen as steadier IGF-1 release in blood compared IGF-1/NP to IGF-1/IGFBP-3 and is also in accordance with our Inhibitors,research,lifescience,medical in vitro results. More stable release of IGF-1 conjugated to NPs can be achieved as compared to protein complexes. The doses used in our study have been the same as in experimental autoimmune encephalomyelitis Inhibitors,research,lifescience,medical mice where positive effects on inflammatory, demyelinating, and demyelinated lesions have been seen when using IGF-1 [55]. Relatively low levels of IGF-1 with or without IGFBP-3 or nanoparticles accumulated to the brains in all studied time points. The amount

crossing the BBB might, however, be sufficient to affect the physiological functions and modulate neuroendocrine and behavioural responses. The sustained release to blood and low tissue concentrations of IFG-1 delivered with nanoparticles may decrease the side effects like hypoglycemia without Inhibitors,research,lifescience,medical losing the therapeutic effect. Low blood and tissue concentrations together with constant and sustained release may be beneficial for the continuous all IGF-1 therapy for INCL. In summary, we have studied the biodistribution and pharmacokinetics of human IGF-1 administrated free or complexed to its natural binding protein IGFBP-3 or nanoparticles in infantile neuronal ceroid lipofuscinosis (INCL) mouse model. IGF-1 conjugated to nanoparticles accumulated and also remained in liver probably in the hepatic veins and sinusoids at high concentration in contrast to IGF-1/IGFPB-3 complex which dissociated and was actively excreted via kidneys and liver during studied time points. Since IGF-1/NP level also in blood decreased moderately compared to IGF-1/IGFBP-3 this data demonstrates steadier release of IGF-1 in to the circulation and XAV-939 datasheet longer bioavailability of IGF-1.